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Abstract
Introduction: Mesenchymal stem cells (MSC) are highly attractive for use in cartilage regeneration. To date, MSC
are usually recruited from subchondral bone marrow using microfracture. Recent data suggest that isolated cells
from adult human articular cartilage, which express the combination of the cell-surface markers CD105 and CD166,
are multi-potent mesenchymal progenitor cells (MPC) with characteristics similar to MSC. MPC within the cartilage
matrix, the target of tissue regeneration, may provide the basis for in situ regeneration of focal cartilage defects.
However, there is only limited information concerning the presence/abundance of CD105
+/CD166
+ MPC in human
articular cartilage. The present study therefore assessed the relative percentage and particularly the zonal
distribution of cartilage MPC using the markers CD105/CD166.
Methods: Specimens of human osteoarthritic (OA; n = 11) and normal (n = 3) cartilage were used for either cell
isolation or immunohistochemistry. Due to low numbers, isolated cells were expanded for 2 weeks and then
analyzed by flow cytometry (FACS) or immunofluorescence in chamber slides for the expression of CD105 and
CD166. Following immunomagnetic separation of CD166
+/
- OA cells, multi-lineage differentiation assays were
performed. Also, the zonal distribution of CD166
+ cells within the matrix of OA and normal cartilage was analyzed
by immunohistochemistry.
Results: FACS analysis showed that 16.7 ± 2.1% (mean ± SEM) of OA and 15.3 ± 2.3 of normal chondrocytes (n.s.)
were CD105
+/CD166
+ and thus carried the established MPC marker combination. Similarly, 13.2% ± 0.9% and 11.7
± 2.1 of CD105
+/CD166
+cells, respectively, were identified by immunofluorescence in adherent OA and normal
chondrocytes. The CD166
+ enriched OA cells showed a stronger induction of the chondrogenic phenotype in
differentiation assays than the CD166
+ depleted cell population, underlining the chondrogenic potential of the
MPC. Strikingly, CD166
+ cells in OA and normal articular cartilage sections (22.1 ± 1.7% and 23.6% ± 1.4%,
respectively; n.s.) were almost exclusively located in the superficial and middle zone.
Conclusions: The present results underline the suitability of CD166 as a biomarker to identify and, in particular,
localize and/or enrich resident MPC with a high chondrogenic potential in human articular cartilage. The
percentage of MPC in both OA and normal cartilage is substantially higher than previously reported, suggesting a
yet unexplored reserve capacity for regeneration.
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Over the past decades, mesenchymal stem cells/
mesenchymal progenitor cells (MSCs/MPCs) have been
discovered in almost all tissues, including peripheral
blood, bone marrow, muscle, fat, pancreas, skin, and
nervous system, and, interestingly, in cartilage [1-5].
Although some of the above non-cartilage MPCs are
accessible more easily and in higher numbers, MPCs
resident in cartilage may be particularly suitable for
novel in situ regeneration strategies, including cell-free
implant materials with or without bioactive components
[6-8].
Compared with numerous reports on classic sources
such as bone marrow, there is only limited information
about the presence of MPCs with defined biomarkers in
human articular cartilage [2-5,9]. Despite extensive
efforts, the emerging field of stem cell research still
strives to establish well-defined marker constellations,
which unambiguously describe the typical stem/progeni-
tor cell phenotype. In the case of cartilage MPCs, most
approaches use markers already successfully described
for other tissues (for example, bone marrow). However,
MPCs isolated from different tissues may not show the
same immunophenotype. Possible strategies to identify
MPCs by their functional characteristics range from
their colony-forming efficacy/clonal growth [10,11] or
differential adhesion to fibronectin [12] to the differen-
tial uptake of cell-penetrating dyes [13] or their ability
to grow out of cartilage tissue [9]. Alternatively, the
expression of typical membrane-associated proteins can
be employed for the selection of MPCs. These include
the expression of Notch-1 [10,14] or triple positivity for
CD44/CD151/CD49c [3] or CD9/CD90/CD166 [4]. In
addition, co-expression of CD105 and CD166 has been
suggested to identify not only bone marrow-derived but
also cartilage MPCs [5,15]. CD105, also known as endo-
glin, is a membrane glycoprotein located on the cell sur-
face. Besides functioning as part of the transforming
growth factor (TGF)-beta receptor complex, it affects
cell morphology and migration and participates in devel-
opmental processes. It has been found on a variety of
cells such as endothelial cells, activated macrophages,
fibroblasts, smooth muscle cells, and the vast majority
of human cartilage chondrocytes [5,16]. The activated
leukocyte cell adhesion molecule (ALCAM), also called
CD166, is a member of the immunoglobulin (Ig) super-
family and a ligand for CD6, which is involved in T-cell
adhesion and co-stimulation [17]. Besides being
expressed on thymic epithelial cells, activated T cells, B-
lymphocytes, and monocytes, CD166 is expressed on a
subpopulation of human cartilage cells [5,18].
Even though the presence of CD105
+/CD166
+ MPCs
in adult human cartilage has been reported before, there
is no information about their localization within the
cartilage matrix. This report is the first to describe their
distribution within adult human articular cartilage. This
knowledge may have implications for currently evolving
concepts in cartilage repair.
Materials and methods
Cartilage preparation
Human osteoarthritis (OA) cartilage was obtained from
t h ek n e ej o i n t so f1 1p a t i e n t sw h oh a dh i g h - g r a d eO A
and who underwent total joint replacement surgery in
the Orthopedic Clinic,W a l d k r a n k e n h a u s‘Rudolf Elle’
GmbH, Eisenberg, Germany (Table 1). Clinical and radi-
ological criteria were used for the classification of OA;
patients with systemic inflammatory diseases such as
rheumatoid arthritis were excluded. Normal cartilage
was obtained from the femoral condyles and tibial pla-
teaus of healthy organ donors or at autopsy from donors
with no known history of joint disease. The study was
approved by the ethics committees of the University
Hospital Jena/Charité-University Medicine Berlin, and
all patients gave their informed consent.
For immunohistological analysis, osteochondral sam-
ples were prepared using a handsaw, directly fixed in 4%
paraformaldehyde in phosphate-buffered saline (PBS),
and then subjected to paraffin embedding. For isolation
of OA cells, cartilage with mild to moderate macro-
scopic alterations was carefully harvested with a scalpel
from the femoral condyles, the tibial plateaus, and the
patella of the knee joints in order to maximize the cell
yield (Figure 1). In the case of cartilage from healthy
donors, all normal-appearing tissue was harvested. To
standardize the procedure and to avoid contamination
of the chondrocytes with bone marrow cells, the sub-
chondral lamella was left intact in all cases. Cartilage
slices were directly transferred into a dish containing
PBS supplemented with antibiotics (100 units/mL peni-
cillin and 100 μg/mL streptomycin).
Isolation and culture of cells from cartilage
Cartilage slices were washed twice in PBS supplemented
with antibiotics and then incubated for 1 hour at 37°C
and 5% carbon dioxide in serum-free DMEM/F12 Nut-
mix (DMEM/F12; Invitrogen, Karlsruhe, Germany) con-
taining 0.1% pronase E (Sigma-Aldrich, Taufkirchen,
Germany) in a spinner flask for fine mincing and diges-
tion. After two further washes, overnight enzymatic
digestion was performed at 37°C in 0.05% collagenase P
(Roche Diagnostics, Mannheim, Germany) in DMEM/
F12 media supplemented with 5% fetal calf serum (FCS).
Cells were separated by filtration through a 50 μm mesh
sieve and washed twice in DMEM/F12 containing 5%
FCS and antibiotics. After counting in a Neubauer
chamber, cells were seeded in culture flasks at an aver-
age density of 2 × 10
4 cells/cm
2, passaged once after 1
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Page 2 of 15week at 90% confluence by trypsin treatment (0.25%
trypsin diluted in Versene; Gibco, now part of Invitro-
gen Corporation, Carlsbad, CA, USA) to eliminate
matrix debris, and cultured for maximally one more
week in order to obtain sufficient numbers of cells.
Media were changed three times a week.
Flow cytometry
After the adherent cells were detached by trypsin treat-
ment, the cell suspension was washed twice in PBS sup-
plemented with 1% FCS and 0.02% sodium azide
(Sigma-Aldrich). A total of 1 × 10
5 cells were double-
stained for 30 minutes at 4°C with R-phycoerythrin-con-
jugated anti-CD105 (clone SN6; IgG1; Ancell Corpora-
tion, Bayport, MN, USA) and fluorescein isothiocyanate-
conjugated anti-CD166 monoclonal antibodies (clone
3A6; IgG1; Ancell Corporation) or the respective IgG1
isotype controls (clone DAK-GO1; Dako, Glostrup, Den-
mark). The cells were then washed three times with 1%
FCS and 0.02% sodium azide, resuspended, and sub-
jected to flow cytometry by using a FACScan and Cell-
Quest software (Becton Dickinson, Heidelberg,
Germany). Cells were gated using forward and side scat-
ters to exclude debris and cell aggregates.
Immunohistochemistry of isolated osteoarthritis and
normal chondrocytes
Cells were grown for 2 to 3 days to subconfluence on
chamber slides covered with DMEM/F12 supplemented
with 5% FCS and antibiotics and then fixed with 4% par-
aformaldehyde for 10 minutes at room temperature.
Non-specific binding sites were blocked with 10%
bovine serum albumin for 30 minutes and then the
slides were stained for 1 hour at room temperature with
10 μg/mL of the primary antibodies directed against
either human CD105 (clone SN6; IgG1; Acris,
Hiddenhausen, Germany) or human CD166 (clone 3A6;
IgG1; Acris). Mouse IgG1 (clone DAK-GO1; Dako)
served as an isotype control. Subsequently, CD105-
stained cells or isotype control slides were incubated
with Alexa Fluor 488-conjugated goat anti-mouse anti-
body (10 μg/mL). CD166-stained cells and the respective
isotype controls were incubated with Alexa Fluor 594-
conjugated goat anti-mouse antibody (10 μg/mL). After
incubation for 1 hour at room temperature, remaining
free binding sites on the first primary antibody were
saturated with unlabeled goat anti-mouse IgG (Sigma-
Aldrich) (10 μg/mL) for 30 minutes at room tempera-
ture. After incubation with the second primary antibody
to human CD105 or human CD166 for 1 hour at room
temperature, secondary antibody was applied as
described above. All respective isotype controls were
negative. Cell nuclei were stained with DAPI (4’,6-diami-
dino-2-phenylindole) and washed twice in PBS; subse-
quently, the chambers were removed, and Prolong
antifade reagent (Molecular Probes, now part of Invitro-
gen Corporation) was applied to the coverslips to pre-
vent photobleaching. Fluorescence-labeled cells were
visualized and photographed by using a fluorescence
microscope (Axiocam MRm; Carl Zeiss, Oberkochen,
Germany) and Axiovision software to create overlay
micrographs of the individual channels. Semiquantitative
analysis was performed by counting three chamber sec-
tors per patient (magnification 100×; total of approxi-
mately 300 cells) for the identification of CD105
+,
CD166
+, and CD105
+/CD166
+ cells.
Immunohistochemistry of osteoarthritis and normal
cartilage
For immunohistochemical labeling, 4-μm-thick tissue
sections were mounted on superfrost plus slides (Men-
zel, Braunschweig, Germany). After deparaffinization in
Table 1 Clinical and radiological characteristics of the patients at the time of total joint replacement surgery
Patient CRP, mg/L ESR, mm/hour ICRS grading score Kellgren-Lawrence grading scale
1 0.3 9 3A 3
2 2.0 7 3A 3
3 1.2 5 3A 3
4 6.3 9 2B 2
5 5.4 19 2A 1
6 0.3 6 3A 3
7 8.1 23 3A 3
8 3.0 12 2A 2
9 10.0 9 3C 4
10 1.7 12 3B 4
11 4.3 12 3B 4
For the parameters of age, C-reactive protein (CRP) (normal range <5 mg/L), and erythrocyte sedimentation rate (ESR) (normal range <30 mm/hour), individual
values are presented; x-ray grading of osteoarthritis was performed on the basis of the Kellgren-Lawrence scale [38], and macroscopic cartilage injury was graded
according to the Hyaline Cartilage Lesion Classification System of the International Cartilage Repair Society (ICRS) [39]. The patient cohort consisted of 3 male and
8 female cartilage donors with a mean age of 69.6 ± 1.6 years and 3 left/8 right affected knee joints.
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a gradient with decreasing proportions of ethanol. To
expose the CD166 molecules, different protocols for
antigen retrieval were tested (for example, enzymatical
digestion of matrix components by chondroitinase ABC,
pronase E, trypsin, collagenase P, or proteinase K).
Finally, a digest with proteinase K (code S3004; Dako)
f o r1 5m i n u t e st u r n e do u tt ob em o s ts u i t a b l es i n c ei t
led to a sufficient degradation of the interfering cartilage
matrix while keeping the sensitive protein structure of
the CD166 molecule intact. Endogenous peroxidase
activity was blocked by 3% hydrogen peroxide in metha-
nol for 15 minutes. The sections were then blocked for
5 minutes with a universal blocking reagent (Ultra UV
Block, TA-125UB; Lab Vision Corporation, now part of
Thermo Fisher Scientific Inc., Fremont, CA, USA) and
incubated overnight at 4°C with unlabeled primary anti-
body to human CD166 (10 μg/mL; rabbit polyclonal;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Normal rabbit IgG instead of the primary antibody was
Figure 1 Image of a representative osteoarthritis cartilage/bone specimen obtained during a total joint replacement surgery. Locations
used for the harvesting of cartilage are indicated by red lines, and excluded regions are encircled with black dotted lines.
Pretzel et al. Arthritis Research & Therapy 2011, 13:R64
http://arthritis-research.com/content/13/2/R64
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non-specifically bound primary antibodies, sections were
treated for 10 minutes with 1 M NaCl in 0.05 M Tris-
buffer pH 7.0. In the next step, binding was detected by
incubating the sections for 1 hour with a complex of
goat anti-rabbit antibody coupled via polymers to horse-
radish peroxidase (UltraVision Detection System;
Thermo Fisher Scientific, Inc.) in accordance with the
instructions of the manufacturer. Using a secondary
antibody with a polymer-coupled detection system
turned out to be superior to a signal-enhancing system
based on biotin in terms of a clearly lower background.
All antibodies were diluted in PBS containing 5%
bovine serum albumin. The signal was developed by
incubation with hydrogen peroxide and DAB (diamino-
benzidine tetrahydrochloride) chromogen. The sections
were washed with PBS between the different incubation
stages, and all steps were performed at room tempera-
ture unless otherwise stated. Sections were counter-
stained with hematoxylin, mounted with aquatex
(Merck, Darmstadt, Germany), and examined by light
microscopy.
Immunomagnetic separation of CD166
+/- cells
Expanded OA chondrocytes (passage 1) were detached
from culture flasks by trypsin treatment and character-
ized by fluorescence-activated cell sorting (FACS) as
above; 1 × 10
7 cells was then placed in a tube contain-
i n g1 0m Lo fD M E M / F 1 2s u p p l e m e n t e dw i t h5 %F C S
and antibiotics. Dynal Magnetic goat anti-mouse IgG
beads (Invitrogen, Karlruhe, Germany) (5 particles per
cell) were washed with PBS and resuspended in sterile
DMEM/F12 supplemented with 5% FCS and antibiotics.
The specific monoclonal anti-CD166 antibodies (1 μg/1
×1 0
6 cells; clone 3A6; Acris) were added to the resus-
pended goat anti-mouse IgG beads and incubated for 20
minutes at 4°C with slight agitation. The goat anti-
mouse IgG beads/anti-CD166 complexes were washed
three times with PBS, resuspended in 1 mL of sterile
medium, and added to the prepared cell suspension.
After incubation for 20 minutes at 4°C with agitation,
the mixture was subjected to magnetic separation for 10
minutes. The supernatant containing the CD166
- cells
was carefully collected, and the pellet of CD166
+ cells
was resuspended in DMEM/F12 with 5% FCS/antibio-
tics. In the case of subsequent expansion, antibody-
microbead complexes were enzymatically detached from
CD166
+ cells by chymopapain treatment for 20 minutes
at 4°C (10 U/10
6 cells; Sigma-Aldrich).
The CD166
+ and CD166
- cells were either immedi-
ately analyzed by FACS or first cultured for up to three
passages to reach the appropriate cell numbers for ana-
lysis of their multi-lineage potential in differentiation
assays and then analyzed by FACS as above.
Cell differentiation assays
For adipogenic differentiation, CD166
+ and CD166
- cells
from patients with OA were plated at a density of
10,000 cells/cm
2 and, 3 days after reaching confluence,
stimulated for 15 days with high-glucose DMEM (Invi-
trogen Corporation) (4,500 mg/L D-glucose) containing
5% human serum and adipogenic supplements: 1 mM
dexamethasone, 0.2 mM indomethacin, and 0.5 mM 3-
isobutyl-1-methylxanthine (all Sigma-Aldrich) and 10
mg/mL insulin (NovoNordisk, Mainz, Germany). Intra-
cellular lipid droplets in adipogenic cultures were visua-
lized by using oil red O (Sigma-Aldrich).
For osteogenic differentiation, CD166
+ and CD166
-
cells were also plated at a density of 10,000 cells/cm
2 in
culture dishes and confluent monolayers were cultured
for 28 days with low-glucose DMEM (1,000 mg/L D-
glucose) containing 5% human serum and osteogenic
supplements (0.1 mM dexamethasone, 50 mM L-ascor-
bic acid-2-phosphate, and 10 mM b-glycerophosphate;
all Sigma-Aldrich). Medium was changed every other
day. Osteogenic differentiation was assessed histochemi-
cally by analyzing alkaline phosphatase activity with
sigma fast BCIP/NBT (5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium) (Sigma-Aldrich).
Chondrogenic differentiation of CD166
+ and CD166
-
cells (passage 3 or 4) was performed under serum-free
conditions in high-density pellet cultures (250,000 cells
per pellet) as described previously [19]. Chondrogenesis
was induced by adding 10 ng/mL TGF-b3 (Peprotech,
Hamburg, Germany). The medium was changed every 2
to 3 days, and cells were maintained for up to 28 days.
Chondrogenic differentiation was assessed by embedding
micro-masses in OCT compound, freezing, and cryosec-
tioning (6 mm). Sections were stained with Alcian blue
(Roth, Karlsruhe, Germany) to detect charged molecules
such as proteoglycans. Controls for the three differentia-
tion experiments were performed by omitting the
respective adipogenic, osteogenic, or chondrogenic
supplements.
Statistics
Results were expressed as mean ± standard error of the
mean. Correlations between the respective percentages
of CD166
+ cells in FACS and immunohistochemical
staining in individual samples were analyzed by using
the one-tailed Spearman rank test (since a negative cor-
relation between the parameters was not expected) and
SPSS 12.0 software (SPSS, Inc., Chicago, IL, USA).
Results
Expressions of CD105 and CD166 on isolated
chondrocytes from osteoarthritis and normal cartilage
FACS analysis of CD105 and CD166 expression on the
surface of chondrocytes from OA patients (n = 11)/
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Page 5 of 15normal donors (n = 3) showed that 21.3% ± 4.7%/5.1% ±
3.9%, respectively, of the cells were double-negative for
CD105 and CD166, 61.0% ± 6.1%/82.4% ± 3.0% were
single-positive for CD105, and only 0.7% ± 0.3%/0.5% ±
0.2% were single-positive for CD166 (Figure 2a). Inter-
estingly, 16.7 ± 2.1%/15.3 ± 2.3% of the analyzed cells
were double-positive for CD105 and CD166 (Figure 2a),
indicating a high percentage of MPCs in adult OA and
normal cartilage.
Immunohistochemical staining of adherent OA (Figure
3a-d,f) and normal (Figure 3e) chondrocytes basically
confirmed these results; that is, 9.3 ± 1.4%/6.2 ± 2.3%,
respectively, of the cells were double-negative for
CD105 and CD166, 77.5% ± 1.9%/88.4% ± 3.2% were
single-positive for CD105, and none was single-positive
for CD166. Also, in this analysis, a large percentage of
cells (that is, 13.2% ± 0.9%/11.7% ± 2.1%) were double-
positive for CD105 and CD166 and thus presumably
MPCs (Figure 3). The Spearman rank test indicated that
there was a significant positive correlation between the
results for FACS and immunohistochemical staining in
individual samples from OA patients (n =6 ,r h o=
0.771, P = 0.036), further underlining the consistency of
the data.
Enrichment of CD166
+ cells from osteoarthritis patients
for multi-lineage assays
After incubation with bead-coupled antibodies to
CD166, both magnetobead-coupled cells and magneto-
bead-free cells were observed; in addition, excess mag-
netobeads were present (Figure 4a1). In contrast,
microscopic analysis of the CD166
+ fraction after mag-
netic separation showed that close to 100% of the cells
carried magnetobeads on their surface (Figure 4b1),
whereas there were no bead-coupled cells in the CD166
-
fraction, pointing to a high efficacy of the separation
(Figure 4c1). To confirm the microscopic evaluation, re-
analysis experiments of the two different fractions by
FACS immediately after separation were performed. For
this purpose, the routinely used enzymatic detachment
of the antibody-microbead complexes from CD166
+
cells was omitted since it causes removal of all cell sur-
face molecules for a period of several days. FACS analy-
sis demonstrated an enrichment of CD166
+ cells from
10% before up to approximately 87% after separation
(Figure 4a2,b2). The negative fraction contained less
than 1% CD166
+ cells (Figure 4c2).
To obtain sufficient numbers of cells for the multi-
lineage assays, CD166
+ and CD166
- cells were expanded
for an additional two or three passages. FACS analysis
immediately before the multi-lineage assay showed that
approximately 40% of the cells in the positive fraction
were still CD166
+ and only approximately 2% of the
cells in the negative fraction were CD166
+.T h i s
indicates that, despite the expansion, considerable
enrichment of CD166
+ cells was achieved (approxi-
mately 20-fold) (Figure 2b,c).
Multi-lineage differentiation assay
In the case of adipogenesis, oil red staining revealed that
CD166
+ as well as CD166
- cells from patients with OA
differentiated toward adipocytes without clear differ-
ences between the two groups (Figure 5a,b). Induction
of the osteogenic lineage, as assessed by the detection of
alkaline phosphatase, was more pronounced in CD166
+
cells, indicating more progenitor cells in CD166
+ than
CD166
- cells (Figure 5c,d). As for chondrogenesis, only
the pellet cultures of CD166
+ cells showed a clear
deposition of extracellular matrix as detected by Alcian
blue staining for sulphated proteoglycans. In contrast,
the CD166
- cell pellets were not characterized by the
formation of cartilage-specific matrix components (Fig-
ure 5e,f).
No signs of osteogenesis were observed in the chon-
drogenic micromass cultures of CD166
+ cells up to 3
weeks, as shown by strong expression of collagen type II
and weak or absent expression of collagen type X and
alkaline phosphatase (Supplemental Table S1 in Addi-
tional file 1). The same was true in chondrocyte micro-
mass culture without chondrogenic supplements, in
which there was no RNA upregulation of alkaline phos-
phatase, collagen type X, or Runx-2 [20] (Supplemental
Figure S1 in Additional file 1).
Immunohistological localization of CD166
+ chondrocytes
within the cartilage matrix
Besides quantifying the relative percentage of CD166
+
chondrocytes by immunofluorescence, analyzing the
zonal distribution of these cells within the matrix of
normal and OA cartilage was of particular interest.
Owing to the inherent autofluorescence properties of
cartilage matrix components and chondrocytes (data not
shown), preliminary tests with fluorescence-based detec-
t i o ns y s t e m sd i dn o tl e a dt ot h ed e s i r e dr e s u l t .I nc o n -
trast, the detection of cell membrane proteins embedded
in the dense extracellular matrix was successfully
accomplished by using a modified protocol by Ozbey
and colleagues [21] (see Materials and methods). Inter-
estingly, the distribution of the CD166
+ cells in OA and
normal samples was not uniform but was clearly zonal
(Figures 6 and 7). In both OA and normal cartilage,
CD166
+ cells were almost exclusively located in the
superficial and middle cartilage zones.
As expected for a cell surface molecule, the staining
signal was associated mainly with chondrocyte mem-
branes and pericellular areas. Specifity of the staining
was supported by the absence of a positive signal in the
isotype control (Figures 6 and 7, right panels).
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Page 6 of 15Figure 2 FACS analysis of CD105 and CD166 expressions on isolated normal and osteoarthritis (OA) chondrocytes and enrichment of
CD166
+ OA cells after immunomagnetic separation. Enzymatically isolated, non-separated OA (n = 11 patients) and normal (n =3 )
chondrocytes were subjected to FACS analysis after initial in vitro culture (a). After magnetic separation of CD166
+ cells, both the positive (b)
and the negative (c) fractions were studied for the expressions of CD105 and CD166. The bar charts show the mean ± standard error of the
mean (SEM) for all analyzed patients; for each section, a representative example of the FACS measurement is included as a dot plot diagram, in
which CD105
+/CD166
+ cells are located in the upper right quadrant. In addition, the relative expressions of CD105 and CD166 (colored lines)
and the corresponding isotype controls (filled graphs) are shown in histograms. FACS, fluorescence-activated cell sorting; FITC, fluorescein
isothiocyanate; RPE, R-phycoerythrin.
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Page 7 of 15Figure 3 Immunohistochemical staining of normal and osteoarthritis (OA) chondrocytes after isolation and initial adherence.
Representative images of an OA chondrocyte sample are shown in (a-d); staining results for normal chondrocytes were identical (not shown).
Nuclei were visualized with DAPI (4’,6-diamidino-2-phenylindole) (a). Cell membranes were double-stained for CD105 by using an Alexa Fluor
488-coupled secondary antibody and for CD166 by using an Alexa Fluor 594-coupled secondary antibody and analyzed by fluorescence
microscopy. Co-expression of CD105 and CD166 was identified after computed superimposition of fluorescence signals from both channels.
Almost all cells are CD105
+ (b), whereas only a few cells express CD166 (c); but in all cases, this is accompanied by the co-expression of CD105
(d). In addition, the results of the quantitative analysis of normal (e) and OA (f) chondrocytes are shown. Magnifications: 100 ×, 400 × (insets).
SEM, standard error of the mean.
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Page 8 of 15Figure 4 Microscopic images and corresponding FACS analysis of chondrocytes before and after immunomagnetic separation.A f t e r
incubation with bead-coupled antibodies to the surface antigen CD166, both membrane-bound and free magnetic anti-CD166 particles are
visible, as are non-labeled chondrocytes (a1). In the positive fraction after separation, only magnetobead-covered CD166
+ cells and free
magnetobeads are present (b1). In the negative fraction, only CD166
- cells without magnetobeads are present; also, no free magnetobeads are
present (c1). These results were confirmed by FACS analysis, demonstrating an enrichment of CD166
+ cells from 10% before (a2) to
approximately 87% after (b2) separation, whereas the negative fraction contained only a very low percentage of CD166
+ cells (c2). FACS,
fluorescence-activated cell sorting; FITC, fluorescein isothiocyanate.
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Page 9 of 15Figure 5 Cell differentiation studies with CD166
+-enriched and -depleted chondrocytes. Isolated osteoarthritis chondrocytes were
immunomagnetically enriched (a,c,e) or depleted (b,d,f) for CD166
+ cells and subjected to adipogenic, osteogenic, and chondrogenic
differentiation. CD166
+-enriched as well as CD166
+-depleted cell populations differentiate to adipocytes after culture in adipogenic medium, as
detected by oil red O staining (a,b). After cultivation with osteogenic medium, both cell populations demonstrate differentiation toward
osteoblasts observable as positive alkaline phosphatase activity within the cells (c,d). However, this effect is more pronounced in cells previously
enriched for CD166
+ chondrocytes (c). Pellet cultures of cells that underwent chondrogenic differentiation are visualized by Alcian blue staining
of newly deposited proteoglycans (e,f). Exclusively, the population with CD166
+-enriched cells shows a clear chondrogenic phenotype (e).
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Page 10 of 15Semiquantitative analysis of stained sections revealed
percentages of 22.1% ± 1.7% CD166
+ chondrocytes
within the total cartilage matrix of OA patient samples
(n = 6) (Figure 6) and 23.6% ± 1.4% in the case of nor-
mal cartilage (n = 3) (Figure 7). Thus, the FACS and
immunhistochemical results obtained for isolated chon-
drocytes were confirmed. The percentages of CD166
+
chondrocytes in the superficial cartilage zone of OA and
normal cartilage were 42.4% ± 7.2%/40.4% ± 2.3%,
respectively; 37.8% ± 4.4%/39.4% ± 1.6% in the middle
zone; and 8.4% ± 2.0%/10.2% ± 1.6% in the deep zone,
whereas no CD166
+ cells were detected in the calcified
zone of either OA or normal cartilage (Figures 6 and 7).
Discussion
Abundance of mesenchymal progenitor cells in
osteoarthritis and normal cartilage
High percentages of CD105
+/CD166
+ cells were
observed by FACS in OA/normal cartilage (16.7 ± 2.1%/
15.3 ± 2.3%, respectively), by immunohistochemical
Figure 6 Distribution of CD166
+ chondrocytes within the osteoarthritis (OA) joint cartilage matrix.C D 1 6 6
+ cells, characterized by an
intense brown staining of the cell membrane and pericellular matrix, are localized primarily in the superficial and middle cartilage zones of OA
cartilage. In contrast, almost no CD166
+ cells are in the deep and calcified cartilage zones. The corresponding isotype control of the
immunohistochemical mesenchymal progenitor cell staining shows an absence of a positive signal, supporting the specificity of the above-
named CD166 staining. Magnifications: 100 × (large micrograph), 400 × (insets). Results of semiquantitative analysis of cartilage samples from six
patients with OA are expressed as mean ± standard error of the mean (SEM).
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and, most importantly, by in situ immunodetection
(22.1% ± 1.7/23.6% ± 1.4%). Since this is an established
marker combination for MPCs [5], considerable num-
bers of these multi-potent cells appear to be present in
OA and normal cartilage.
The present percentages are higher than those in pre-
vious reports (2% to 12% [4] or approximately 7.5% [5],
respectively), thus suggesting a yet unexplored reserve
capacity for regeneration, especially in OA cartilage.
However, the chondrocytes in previous studies were
analyzed either immediately following enzymatic harvest
Figure 7 Distribution of CD166
+ chondrocytes within the normal joint cartilage matrix. CD166
+ cells within normal cartilage matrix show
a distribution pattern similar to that of osteoarthritic cartilage (shown in Figure 6), and the absence of a positive staining signal in the
corresponding isotype control proves the specificity of the CD166 staining. Magnifications: 100 × (large micrograph), 400 × (insets). Results of
semiquantitative analysis of cartilage samples from three normal donors are expressed as mean ± standard error of the mean (SEM).
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Page 12 of 15[4] or after short-term primary culture (P0) [5,22]. It is
therefore possible that the initial expansion of MPCs for
2 weeks in the present study led to a relative increase of
the cells and an overestimation of the percentage of
MPCs in native OA cartilage [4]. This is somewhat unli-
kely since the percentage of CD166
+ cells decreased
from approximately 87% immediately following separa-
tion to approximately 40% after culture for approxi-
mately 3 weeks. Also, the percentage of CD166
+ cells in
OA and normal cartilage sections was comparable to or
even higher than that in FACS or staining of isolated
cells in culture. On the other hand, heterogeneity
among patient cohorts in different studies or differences
in the preparation techniques (such as the inclusion/
exclusion of the calcified cartilage, which represents up
to 30% of the total cartilage [23]) may have influenced
the results.
In the present study, in contrast to previous reports
[5,14], the percentage of MPCs did not differ in OA and
normal cartilage. One potential explanation could be that,
in the present study, cartilage samples were exclusively
obtained from areas with mild to moderate macroscopic
alterations - which may contain higher numbers of vital
MPCs. However, no differences concerning the percen-
tages of CD105
+/CD166
+ MPCs in normal-appearing and
degraded OA cartilage have been previously observed [5].
In addition, severe alterations of the metabolic functions in
OA chondrocytes (and presumably of MPCs) do not seem
to be restricted to the lesioned areas but appear to affect
the complete cartilage in OA joints [24]. In view of the
high percentages of MPCs in OA cartilage and the fact that
at least bone marrow-derived MSCs from OA patients do
not show a lower chondrogenic potential than MSCs from
normal donors [25,26], future studies may have to explicitly
focus on exploiting the regenerative potential of OA MPCs.
Suitability of CD166 as a sole biomarker for mesenchymal
progenitor cells in cartilage
It is believed that MPCs in cartilage co-express the mar-
kers CD105 and CD166 and that there are no CD166
-
MPCs. Since approximately 99% of the MPCs in the
present study co-expressed CD105 and CD166, CD105
may be dispensable and CD166 may suffice to unequivo-
cally identify and enrich MPCs from cartilage. This is in
line with the fact that CD166 acts as a central mediator
in cell adhesion, growth, and migration [27]. Indeed,
CD166
+ cells from OA patients were somewhat more
potent in osteogenesis and were the only cells capable
of undergoing chondrogenesis under the respective cul-
ture conditions. The lack of increased capacity of
CD166
+ cells for adipogenesis may be due to the
advanced stage of OA in the cartilage donors [28]. On
the other hand, the CD166
- chondrocytes showed some
limited multipotency in the present assays, indicating
that there may also be CD166
- MPCs in cartilage [5].
Whether the minute fraction of CD166
+/CD105
- cells in
cartilage also carries MPC features needs to be further
analyzed.
Zonal distribution of CD166
+ mesenchymal progenitor
cells in the cartilage matrix
CD166
+ chondrocytes were almost exclusively located in
the superficial and middle zones of OA and normal car-
tilage. This zonal preference confirms a previous report
in normal rat cartilage [10] and extends the findings to
human OA and normal cartilage. Indeed, the surface
zone seems to be of central importance for the growth
of articular cartilage in young animals [29] and presum-
ably relies on a progenitor cell population located in
this zone [30]. Also, in rat and cow, these progenitor
cells carry specific stem cell markers such as Notch-1
and CD166 [10,21], showing the high consistency of this
zonal enrichment among species. The MPC marker
CD166 could thus serve as a valuable tool to improve
matrix-based cartilage regeneration strategies concerning
their specific three-dimensional design, the addition of
cell-recruiting bioactive factors, and/or optimized seed-
ing with cartilage-derived MPCs [28,31-33]. This is of
special interest since newer repair strategies using cell-
free matrices in combination with microfracturing
aimed at mobilizing resident multi-potent MPCs from
the bone marrow have shown the feasibility of such con-
cepts and have entered clinical practice [34-37].
Conclusions
The present study suggests that CD166 is a suitable bio-
marker for the identification and localization of resident
MPCs with high chondrogenic potential in human
articular cartilage. In addition, the percentage of MPCs
in OA and normal cartilage is substantially higher than
previously reported, indicating a yet unexplored reserve
capacity for regeneration in the event of chondral degra-
dation. The knowledge about their preferred localization
in the superficial and middle zones of OA and normal
cartilage may open new therapeutic opportunities con-
cerning both matrix-based cell-containing implants and
cell-free in situ regeneration.
Additional material
Additional file 1: Additional data concerning the differentiation
status of chondrocyte micromasses. The file contains data from the
immunohistological characterization of CD166
+-enriched micromasses
after culture in chondrogenic medium as well as gene expression profiles
of selected marker genes for hypertrophy and/or osteogenic lineage
development in human chondrocyte high-density micromasses.
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DMEM/F12 Nutmix: Dulbecco’s modified Eagle’s medium/F12 Nutmix; FACS:
fluorescence-activated cell sorting; FCS: fetal calf serum; IgG:
immunoglobulin G; MPC: mesenchymal progenitor cell; MSC: mesenchymal
stem cell; OA: osteoarthritis; PBS: phosphate-buffered saline; TGF:
transforming growth factor.
Acknowledgements
The authors thank Katja Neumann and Samuel Vetterlein from TransTissue
Technologies (Berlin) for excellent cooperation concerning the cell
differentiation assays. We are grateful to Olaf Brinkmann, Renée Fuhrmann,
Andreas Roth, Andreas Wagner, and Rando Winter (Clinic of Orthopedics,
University Hospital Jena, Waldkrankenhaus ‘Rudolf Elle’, Eisenberg) for
providing patient material and to Cordula Müller and Jana Schömburg for
excellent technical assistance. We thank Wolf-D. Wetzel (Department of
Radiology, Waldkrankenhaus ‘Rudolf Elle’, Eisenberg) for evaluating
preoperative x-rays according to the Kellgren-Lawrence grading scale. This
study was supported by the Federal Ministry of Education and Research
grants FKZ 13N9833 and FKZ 035577D (to RWK) as well as FKZ 13N9827 (to
CK).
Author details
1Experimental Rheumatology Unit, Department of Orthopedics, University
Hospital Jena, Klosterlausnitzer Str. 81, Eisenberg, D-07607, Germany.
2Laboratory of Organic and Macromolecular Chemistry, Friedrich-Schiller-
University Jena, Humboldtstr. 10, Jena, D-07743, Germany.
3TransTissue
Technologies, Charitéplatz 1/Virchowweg 11, Berlin, D-10117, Germany.
4Department of Medicine, Division of Rheumatology & Clinical Immunology,
P.O. Box 2951, Mafraq Hospital, Abu Dhabi, United Arab Emirates.
Authors’ contributions
DP and SA contributed to study conception and design, acquisition of data,
analysis and interpretation of data, and drafting or critical revision of the
manuscript or both. CK and RWK contributed to study conception and
design, analysis and interpretation of data, and drafting or critical revision of
the manuscript or both. SL contributed to acquisition of data, analysis and
interpretation of data, and drafting and critical revision of the manuscript. SR
contributed to acquisition of data and critical revision of the manuscript. ME
contributed to acquisition of data and to critical revision of the manuscript.
All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 July 2010 Revised: 15 February 2011
Accepted: 15 April 2011 Published: 15 April 2011
References
1. Csaki C, Schneider PR, Shakibaei M: Mesenchymal stem cells as a potential
pool for cartilage tissue engineering. Ann Anat 2008, 190:395-412.
2. Karlsson C, Stenhamre H, Sandstedt J, Lindahl A: Neither Notch1
expression nor cellular size correlate with mesenchymal stem cell
properties of adult articular chondrocytes. Cells Tissues Organs 2008,
187:275-285.
3. Grogan SP, Barbero A, Diaz-Romero J, Cleton-Jansen AM, Soeder S,
Whiteside R, Hogendoorn PC, Farhadi J, Aigner T, Martin I, Mainil-Varlet P:
Identification of markers to characterize and sort human articular
chondrocytes with enhanced in vitro chondrogenic capacity. Arthritis
Rheum 2007, 56:586-595.
4. Fickert S, Fiedler J, Brenner RE: Identification of subpopulations with
characteristics of mesenchymal progenitor cells from human
osteoarthritic cartilage using triple staining for cell surface markers.
Arthritis Res Ther 2004, 6:R422-R432.
5. Alsalameh S, Amin R, Gemba T, Lotz M: Identification of mesenchymal
progenitor cells in normal and osteoarthritic human articular cartilage.
Arthritis Rheum 2004, 50:1522-1532.
6. Richter W: Mesenchymal stem cells and cartilage in situ regeneration. J
Intern Med 2009, 266:390-405.
7. Bedi A, Feeley BT, Williams RJ III: Management of articular cartilage
defects of the knee. J Bone Joint Surg Am 2010, 92:994-1009.
8. Zippel N, Schulze M, Tobiasch E: Biomaterials and mesenchymal stem
cells for regenerative medicine. Recent Pat Biotechnol 2010, 4:1-22.
9. Koelling S, Kruegel J, Irmer M, Path JR, Sadowski B, Miro X, Miosge N:
Migratory chondrogenic progenitor cells from repair tissue during the
later stages of human osteoarthritis. Cell Stem Cell 2009, 4:324-335.
10. Dowthwaite GP, Bishop JC, Redman SN, Khan IM, Rooney P, Evans DJ,
Haughton L, Bayram Z, Boyer S, Thomson B, Wolfe MS, Archer CW: The
surface of articular cartilage contains a progenitor cell population. J Cell
Sci 2004, 117:889-897.
11. Barbero A, Ploegert S, Heberer M, Martin I: Plasticity of clonal populations
of dedifferentiated adult human articular chondrocytes. Arthritis Rheum
2003, 48:1315-1325.
12. Khan IM, Bishop JC, Gilbert S, Archer CW: Clonal chondroprogenitors
maintain telomerase activity and Sox9 expression during extended
monolayer culture and retain chondrogenic potential. Osteoarthritis
Cartilage 2009, 17:518-528.
13. Hattori S, Oxford C, Reddi AH: Identification of superficial zone articular
chondrocyte stem/progenitor cells. Biochem Biophys Res Commun 2007,
358:99-103.
14. Hiraoka K, Grogan S, Olee T, Lotz M: Mesenchymal progenitor cells in
adult human articular cartilage. Biorheology 2006, 43:447-454.
15. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL: Phenotypic
and functional comparison of cultures of marrow-derived mesenchymal
stem cells (MSCs) and stromal cells. J Cell Physiol 1998, 176:57-66.
16. Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM, Banville D, Vary CP,
Bernabeu C: Endoglin regulates cytoskeletal organization through
binding to ZRP-1, a member of the Lim family of proteins. J Biol Chem
2004, 279:32858-32868.
17. Bowen MA, Aruffo A: Adhesion molecules, their receptors, and their
regulation: analysis of CD6-activated leukocyte cell adhesion molecule
(ALCAM/CD166) interactions. Transplant Proc 1999, 31:795-796.
18. Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H,
Neubauer M, Pesando JM, Francke U: Cloning, mapping, and
characterization of activated leukocyte-cell adhesion molecule (ALCAM),
a CD6 ligand. J Exp Med 1995, 181:2213-2220.
19. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU: In vitro
chondrogenesis of bone marrow-derived mesenchymal progenitor cells.
Exp Cell Res 1998, 238:265-272.
20. Dehne T, Schenk R, Perka C, Morawietz L, Pruss A, Sittinger M, Kaps C,
Ringe J: Gene expression profiling of primary human articular
chondrocytes in high-density micromasses reveals patterns of recovery,
maintenance, re- and dedifferentiation. Gene 2010, 462:8-17.
21. Ozbey O, Sahin Z, Ozenci AM, Acar N, Ustunel I: The effect of systemic
corticosteroid treatment on the immunolocalisation of Notch-1, Delta,
CD105 and CD166 in rat articular cartilage. Acta Histochem 2010,
112:424-431.
22. Diaz-Romero J, Gaillard JP, Grogan SP, Nesic D, Trub T, Mainil-Varlet P:
Immunophenotypic analysis of human articular chondrocytes: changes
in surface markers associated with cell expansion in monolayer culture.
J Cell Physiol 2005, 202:731-742.
23. Mika J, Clanton TO, Pretzel D, Schneider G, Ambrose CG, Kinne RW: Surgical
preparation for articular cartilage regeneration without penetration of
the subchondral bone plate: in vitro and in vivo studies in humans and
sheep. Am J Sports Med 2011, 39:624-631.
24. Aurich M, Mwale F, Reiner A, Mollenhauer JA, Anders JO, Fuhrmann RA,
Kuettner KE, Poole AR, Cole AA: Collagen and proteoglycan turnover in
focally damaged human ankle cartilage: evidence for a generalized
response and active matrix remodeling across the entire joint surface.
Arthritis Rheum 2006, 54:244-252.
25. Scharstuhl A, Schewe B, Benz K, Gaissmaier C, Buhring HJ, Stoop R:
Chondrogenic potential of human adult mesenchymal stem cells is
independent of age or osteoarthritis etiology. Stem Cells 2007,
25:3244-3251.
26. Hollander AP, Dickinson SC, Sims TJ, Brun P, Cortivo R, Kon E, Marcacci M,
Zanasi S, Borrione A, De Luca C, Pavesio A, Soranzo C, Abatangelo G:
Maturation of tissue engineered cartilage implanted in injured and
osteoarthritic human knees. Tissue Eng 2006, 12:1787-1798.
27. Swart GW: Activated leukocyte cell adhesion molecule (CD166/ALCAM):
developmental and mechanistic aspects of cell clustering and cell
migration. Eur J Cell Biol 2002, 81:313-321.
Pretzel et al. Arthritis Research & Therapy 2011, 13:R64
http://arthritis-research.com/content/13/2/R64
Page 14 of 1528. Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F: Reduced
chondrogenic and adipogenic activity of mesenchymal stem cells from
patients with advanced osteoarthritis. Arthritis Rheum 2002, 46:704-713.
29. Hunziker EB, Kapfinger E, Geiss J: The structural architecture of adult
mammalian articular cartilage evolves by a synchronized process of
tissue resorption and neoformation during postnatal development.
Osteoarthritis Cartilage 2007, 15:403-413.
30. Hayes AJ, MacPherson S, Morrison H, Dowthwaite G, Archer CW: The
development of articular cartilage: evidence for an appositional growth
mechanism. Anat Embryol (Berl) 2001, 203:469-479.
31. Kreuz PC, Muller S, Ossendorf C, Kaps C, Erggelet C: Treatment of focal
degenerative cartilage defects with polymer-based autologous
chondrocyte grafts: four-year clinical results. Arthritis Res Ther 2009, 11:
R33.
32. Nehrer S, Domayer S, Dorotka R, Schatz K, Bindreiter U, Kotz R: Three-year
clinical outcome after chondrocyte transplantation using a hyaluronan
matrix for cartilage repair. Eur J Radiol 2006, 57:3-8.
33. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M: Human
autologous culture expanded bone marrow mesenchymal cell
transplantation for repair of cartilage defects in osteoarthritic knees.
Osteoarthritis Cartilage 2002, 10:199-206.
34. Behrens P: Matrix-coupled microfracture -a new concept for cartilage
defect repair. Arthroskopie 2005, 3:193-197.
35. Steinwachs MR, Guggi T, Kreuz PC: Marrow stimulation techniques. Injury
2008, 39(Suppl 1):S26-31.
36. Erggelet C, Neumann K, Endres M, Haberstroh K, Sittinger M, Kaps C:
Regeneration of ovine articular cartilage defects by cell-free polymer-
based implants. Biomaterials 2007, 28:5570-5580.
37. Zantop T, Peterson W: Arthroscopic implantation of a matrix to cover
large chondral defect during microfracture. Arthroscopy 2011,
25:1354-1360.
38. Kellgren JH, Lawrence JS: Radiological assessment of osteo-arthrosis. Ann
Rheum Dis 1957, 16:494-502.
39. Brittberg M, Winalski CS: Evaluation of cartilage injuries and repair. J Bone
Joint Surg Am 2003, 85-A(Suppl 2):58-69.
doi:10.1186/ar3320
Cite this article as: Pretzel et al.: Relative percentage and zonal
distribution of mesenchymal progenitor cells in human osteoarthritic
and normal cartilage. Arthritis Research & Therapy 2011 13:R64.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pretzel et al. Arthritis Research & Therapy 2011, 13:R64
http://arthritis-research.com/content/13/2/R64
Page 15 of 15